RTI Biologics, Inc. (RTIX) Tops Q1 EPS by 1c; Guides Q2, Updates FY12

RTI Biologics, Inc. (NASDAQ: RTIX) reported Q1 EPS of $0.04, $0.01 better than the analyst estimate of $0.03. Revenue for the quarter came in at $43.7 million versus the consensus estimate of $41.91 million.

RTI Biologics, Inc. sees Q2 2012 EPS of $0.04, versus the consensus of $0.04. RTI Biologics, Inc. sees Q2 2012 revenue of $43-$44 million, versus the consensus of $44.18 million.

RTI Biologics, Inc. sees FY2012 EPS of $0.16-$0.17, versus prior guidance of $0.15-$0.17 and the consensus of $0.16. RTI Biologics, Inc. sees FY2012 revenue of $176-$178 million, versus the consensus of $175.7 million.

For earnings history and earnings-related data on RTI Biologics, Inc. (RTIX) click here.

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
• Newton Golf Company (NWTG) Reports Q2 Loss of $0.49
• Diana Shipping withdraws bid to acquire Genco Shipping